Jim. M. Smit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jim. M. Smit has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Diederik Gommers
Erasmus MC
7 shared publications - Jesse H. Krijthe
Delft University of Technology, Delft, Netherlands
7 shared publications - Marcel J. T. Reinders
Pattern Recognition & Bioinformatics group, Delft University of Technology, Delft, The Netherlands
6 shared publications - Jasper van Bommel
Department of Adult Intensive Care, Erasmus University Medical Center, Rotterdam, the Netherlands
5 shared publications Jesse H. Krijthe
Pattern Recognition & Bioinformatics group, Delft University of Technology, Delft, The Netherlands
5 shared publications- Annemijn H. Jonkman
Department of Intensive Care, Erasmus MC, Rotterdam, The Netherlands
4 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1)
Switching from controlled to assisted ventilation based on oxygenation thresholds and PEEP: a target trial emulation
Objective: To determine whether PaO 2 /FiO 2 -based dynamic treatment strategies can optimise the timing of switching from controlled to assisted ventilation. Design and setting: Target trial emulation using the MIMIC-IV database v3.1 (2008–2022). Patients: Adult ICU patients on controlled invasive mechanical ventilation (IMV) for ≥ 48 h with at least one PaO 2 /FiO 2 2 /FiO 2 exceeded predefined thresholds (150, 200, or 250 mmHg). Additionally, to account for possible PEEP-dependent effects, the thresholds were evaluated depending on the set PEEP (< 8 vs. ≥8 cmH 2 O), yielding nine strategies. Outcomes were 28-day restricted mean time lost (RMTL) to successful extubation (where a lower RMTL indicates a longer time to extubation) and mortality. Measurements and main results: Among 1,635 patients, the strategy of delaying the switch until PaO 2 /FiO 2 >250 mmHg showed a longer time to successful extubation compared to switching at > 150 mmHg or > 200 mmHg (RMTL 17.4 days [95% CI: 15.9–18.6] vs. 19.6 days [95% CI: 18.6–20.9] and 19.8 days [95% CI: 18.5–21.1], respectively). Exploratory PEEP-dependent analyses demonstrated the longest time to successful extubation with ‘>250 mmHg’ for both low and high PEEP and the shortest with ‘>150 mmHg for low PEEP; >200 mmHg for high PEEP’. Among patients ventilated for ≥ 24 h, the 150 mmHg threshold was most favourable, irrespective of PEEP. No mortality differences were observed across strategies. Conclusions: Switching as soon as PaO 2 /FiO 2 >150 mmHg is generally favoured over delaying until > 250 mmHg. Patients requiring ≥ 48 h of controlled IMV with PEEP ≥ 8 cmH 2 O may potentially benefit from a slightly higher threshold (> 200 mmHg). Prospective validation is warranted.
- 20 August 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1)
Open AccessSwitching from controlled to assisted ventilation based on oxygenation thresholds and PEEP: a target trial emulation
Objective: To determine whether PaO 2 /FiO 2 -based dynamic treatment strategies can optimise the timing of switching from controlled to assisted ventilation. Design and setting: Target trial emulation using the MIMIC-IV database v3.1 (2008–2022). Patients: Adult ICU patients on controlled invasive mechanical ventilation (IMV) for ≥ 48 h with at least one PaO 2 /FiO 2 2 /FiO 2 exceeded predefined thresholds (150, 200, or 250 mmHg). Additionally, to account for possible PEEP-dependent effects, the thresholds were evaluated depending on the set PEEP (< 8 vs. ≥8 cmH 2 O), yielding nine strategies. Outcomes were 28-day restricted mean time lost (RMTL) to successful extubation (where a lower RMTL indicates a longer time to extubation) and mortality. Measurements and main results: Among 1,635 patients, the strategy of delaying the switch until PaO 2 /FiO 2 >250 mmHg showed a longer time to successful extubation compared to switching at > 150 mmHg or > 200 mmHg (RMTL 17.4 days [95% CI: 15.9–18.6] vs. 19.6 days [95% CI: 18.6–20.9] and 19.8 days [95% CI: 18.5–21.1], respectively). Exploratory PEEP-dependent analyses demonstrated the longest time to successful extubation with ‘>250 mmHg’ for both low and high PEEP and the shortest with ‘>150 mmHg for low PEEP; >200 mmHg for high PEEP’. Among patients ventilated for ≥ 24 h, the 150 mmHg threshold was most favourable, irrespective of PEEP. No mortality differences were observed across strategies. Conclusions: Switching as soon as PaO 2 /FiO 2 >150 mmHg is generally favoured over delaying until > 250 mmHg. Patients requiring ≥ 48 h of controlled IMV with PEEP ≥ 8 cmH 2 O may potentially benefit from a slightly higher threshold (> 200 mmHg). Prospective validation is warranted.
- 17 June 2026
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 14 (7) , e44-e45
Precision-guided immunomodulatory therapy in sepsis
- 17 June 2026
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 14 (7) , e44-e45
Precision-guided immunomodulatory therapy in sepsis
- Open Access
- 25 April 2026
- Published by Springer Nature in Pneumonia
- Vol. 18 (1) , 9
The heterogeneous treatment effect of adjuvant therapy with corticosteroids in patients with Community-Acquired Pneumonia: a review
Randomized Controlled Trials (RCTs) assessing adjuvant corticosteroids for hospitalized Community-Acquired Pneumonia (CAP) show mixed results, suggesting Heterogeneity of Treatment Effect (HTE). Current guidelines conflict: some restrict use to septic shock, while others advocate for broader application in severe CAP. Among three recent, large RCTs focused on severe CAP, however, only one demonstrated significant benefit, raising the question: should severity-based treatment guidance really be preferred?. The debate surrounding corticosteroid use in CAP is complicated by two issues: the lack of a unified definition for ‘severe CAP’, with definitions either based on the American Thoracic Society criteria or severity scores like the Pneumonia Severity Index, and the reliance on Aggregate Data Meta-Analyses (ADMAs). ADMAs synthesize trial results by categorizing entire RCTs as severe or non-severe, while most RCT populations included patients with varying disease severities. Individual Patient Data Meta-Analyses (IPDMAs) enable stratification on a patient-level. Our recent IPDMA utilized multivariate predictive HTE modelling in six RCT datasets to identify patient characteristics predicting corticosteroid benefit, which suggested C-reactive protein (CRP) as a predictor of benefit. Therefore, this finding was externally validated in two other RCTs, revealing statistically significant HTE found across baseline CRP subgroups (i.e., ≤ 204 mg/L vs. >204 mg/L), while no such HTE was found across severity-based subgroups. These findings may advocate for corticosteroid treatment guided by CRP instead of disease severity. CRP, however, is unlikely the sole driver of corticosteroids benefit, as other potential sources of HTE like imaging or cytokines (‘known unknowns’) or other unmeasured variables (‘ unknown unknowns’) may exist, and moreover, our IPDMA post-hoc suggested HTE across aetiology and treatment timing. Moving forward, the efficacy of precision medicine in CAP hinges on rigorous replication of HTE findings —being notoriously susceptible to false positives— in independent datasets, and harmonized and standardized data collection in future trials. Based on current evidence, CRP may serve as a pragmatic tool to guide corticosteroid treatment, but given to the drug’s “pendulum swings” from broad use to avoidance over the last decades, caution remains essential.
- 25 April 2026
- Published by Springer Nature in Pneumonia
- Vol. 18 (1) , 9
Open AccessThe heterogeneous treatment effect of adjuvant therapy with corticosteroids in patients with Community-Acquired Pneumonia: a review
Randomized Controlled Trials (RCTs) assessing adjuvant corticosteroids for hospitalized Community-Acquired Pneumonia (CAP) show mixed results, suggesting Heterogeneity of Treatment Effect (HTE). Current guidelines conflict: some restrict use to septic shock, while others advocate for broader application in severe CAP. Among three recent, large RCTs focused on severe CAP, however, only one demonstrated significant benefit, raising the question: should severity-based treatment guidance really be preferred?. The debate surrounding corticosteroid use in CAP is complicated by two issues: the lack of a unified definition for ‘severe CAP’, with definitions either based on the American Thoracic Society criteria or severity scores like the Pneumonia Severity Index, and the reliance on Aggregate Data Meta-Analyses (ADMAs). ADMAs synthesize trial results by categorizing entire RCTs as severe or non-severe, while most RCT populations included patients with varying disease severities. Individual Patient Data Meta-Analyses (IPDMAs) enable stratification on a patient-level. Our recent IPDMA utilized multivariate predictive HTE modelling in six RCT datasets to identify patient characteristics predicting corticosteroid benefit, which suggested C-reactive protein (CRP) as a predictor of benefit. Therefore, this finding was externally validated in two other RCTs, revealing statistically significant HTE found across baseline CRP subgroups (i.e., ≤ 204 mg/L vs. >204 mg/L), while no such HTE was found across severity-based subgroups. These findings may advocate for corticosteroid treatment guided by CRP instead of disease severity. CRP, however, is unlikely the sole driver of corticosteroids benefit, as other potential sources of HTE like imaging or cytokines (‘known unknowns’) or other unmeasured variables (‘ unknown unknowns’) may exist, and moreover, our IPDMA post-hoc suggested HTE across aetiology and treatment timing. Moving forward, the efficacy of precision medicine in CAP hinges on rigorous replication of HTE findings —being notoriously susceptible to false positives— in independent datasets, and harmonized and standardized data collection in future trials. Based on current evidence, CRP may serve as a pragmatic tool to guide corticosteroid treatment, but given to the drug’s “pendulum swings” from broad use to avoidance over the last decades, caution remains essential.
- Open Access
Physiological subphenotypes of ARDS: Prognostic and predictive enrichment for PEEP strategy
Background: Acute respiratory distress syndrome (ARDS) is characterised by substantial physiological heterogeneity, which contribute to a very variable clinical outcomes and therefore inconsistent responses to ventilatory strategies. We aimed to externally validate physiological ARDS subphenotypes previously identified using routine ventilatory and gas-exchange variables, assess their prognostic relevance across independent cohorts, and examine heterogeneity of treatment effect according to PEEP strategy. Methods: Unsupervised Gaussian Mixture Modelling was used to identify physiological subphenotypes based on ventilatory mechanics and gas-exchange parameters. Labels were subsequently used to train and validate supervised classifiers using XGBoost. Prognostic relevance was assessed across three independent cohorts, including two randomised controlled trials (ALVEOLI and LOVS). Predictive enrichment for PEEP strategy was evaluated using individual patient data from ALVEOLI and LOVS (n = 1,532) using intention-to-treat analyses, applying both one-stage and two-stage fixed-effects IPD meta-analytic approaches to test for interaction between physiological subphenotype and PEEP strategy. Results: Two distinct physiological subphenotypes, termed Efficient and Restrictive, were replicated across independent cohorts. Across each cohort, patients classified as Restrictive consistently exhibited higher all-cause 28-day mortality compared to Efficient patients. When pooled across studies, the Restrictive subphenotype was associated with a significantly increased risk of death (pooled odds ratio 1.75, 95% CI 1.36–2.24), with no evidence of between-study heterogeneity. Predictive analyses showed a statistically significant interaction between physiological subphenotype and PEEP strategy in the one-stage IPD model (p for interaction = 0.037), with concordant findings in the two-stage fixed-effects IPD meta-analysis (interaction OR 1.91, 95% CI 1.00–3.66; I² = 0%). Higher PEEP was associated with increased mortality in Efficient patients and reduced mortality in Restrictive patients, indicating effect modification by physiological subphenotype. Interpretation: Physiological ARDS subphenotypes derived from routinely collected bedside data provide robust and externally validated prognostic stratification across observational and randomised trial cohorts. The observed interaction with PEEP strategy suggests that underlying physiological profiles may influence treatment response, supporting the concept that physiology-based be a starting point for personalized medicine and therefore better ventilatory strategies in future clinical trials.
Open AccessPhysiological subphenotypes of ARDS: Prognostic and predictive enrichment for PEEP strategy
Background: Acute respiratory distress syndrome (ARDS) is characterised by substantial physiological heterogeneity, which contribute to a very variable clinical outcomes and therefore inconsistent responses to ventilatory strategies. We aimed to externally validate physiological ARDS subphenotypes previously identified using routine ventilatory and gas-exchange variables, assess their prognostic relevance across independent cohorts, and examine heterogeneity of treatment effect according to PEEP strategy. Methods: Unsupervised Gaussian Mixture Modelling was used to identify physiological subphenotypes based on ventilatory mechanics and gas-exchange parameters. Labels were subsequently used to train and validate supervised classifiers using XGBoost. Prognostic relevance was assessed across three independent cohorts, including two randomised controlled trials (ALVEOLI and LOVS). Predictive enrichment for PEEP strategy was evaluated using individual patient data from ALVEOLI and LOVS (n = 1,532) using intention-to-treat analyses, applying both one-stage and two-stage fixed-effects IPD meta-analytic approaches to test for interaction between physiological subphenotype and PEEP strategy. Results: Two distinct physiological subphenotypes, termed Efficient and Restrictive, were replicated across independent cohorts. Across each cohort, patients classified as Restrictive consistently exhibited higher all-cause 28-day mortality compared to Efficient patients. When pooled across studies, the Restrictive subphenotype was associated with a significantly increased risk of death (pooled odds ratio 1.75, 95% CI 1.36–2.24), with no evidence of between-study heterogeneity. Predictive analyses showed a statistically significant interaction between physiological subphenotype and PEEP strategy in the one-stage IPD model (p for interaction = 0.037), with concordant findings in the two-stage fixed-effects IPD meta-analysis (interaction OR 1.91, 95% CI 1.00–3.66; I² = 0%). Higher PEEP was associated with increased mortality in Efficient patients and reduced mortality in Restrictive patients, indicating effect modification by physiological subphenotype. Interpretation: Physiological ARDS subphenotypes derived from routinely collected bedside data provide robust and externally validated prognostic stratification across observational and randomised trial cohorts. The observed interaction with PEEP strategy suggests that underlying physiological profiles may influence treatment response, supporting the concept that physiology-based be a starting point for personalized medicine and therefore better ventilatory strategies in future clinical trials.
- 21 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 1073-1074
From severity-guided to C-reactive protein–guided corticosteroid treatment
- 21 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 1073-1074
From severity-guided to C-reactive protein–guided corticosteroid treatment
- Open Access
- 22 January 2026
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 10
Applications and implicit assumptions in dementia risk scores: A scoping review of the LIBRA score
Dementia risk scores are commonly used tools to estimate the risk of developing Alzheimer's disease and dementia. We lack an overview of what risk scores are used for, what is claimed they ought to be used for, and whether they are suitable for these applications. To address this, we use the ‘Lifestyle for Brain Health’ (LIBRA) score as a representative example risk score and conduct a literature review to study its applications. The goals of this study are (1) to create an overview of how the LIBRA score has been utilized in scientific articles, (2) to record other applications that these same articles mention, and (3) to critically assess whether LIBRA is suitable for these applications. Of the 66 articles included in our review, 36 involved analyzing associations of LIBRA with dementia, cognition, or other outcomes. We also identified several other applications, with 32 articles mentioning LIBRA as an estimate of ‘dementia prevention potential’, 6 articles used LIBRA as a surrogate outcome for their trial or intervention, and 7 articles mentioned that it could help support clinician decisions in practice. Although there is a clear need for tools that can be used for these applications, the amount of evidence supporting the suitability of dementia risk scores for many of these applications is limited. We recommend that researchers transparently report the purposes of these dementia risk scores, which may include causal tasks, and that research is done to evaluate whether it is valid to use these scores in this way.
- 22 January 2026
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 10
Open AccessApplications and implicit assumptions in dementia risk scores: A scoping review of the LIBRA score
Dementia risk scores are commonly used tools to estimate the risk of developing Alzheimer's disease and dementia. We lack an overview of what risk scores are used for, what is claimed they ought to be used for, and whether they are suitable for these applications. To address this, we use the ‘Lifestyle for Brain Health’ (LIBRA) score as a representative example risk score and conduct a literature review to study its applications. The goals of this study are (1) to create an overview of how the LIBRA score has been utilized in scientific articles, (2) to record other applications that these same articles mention, and (3) to critically assess whether LIBRA is suitable for these applications. Of the 66 articles included in our review, 36 involved analyzing associations of LIBRA with dementia, cognition, or other outcomes. We also identified several other applications, with 32 articles mentioning LIBRA as an estimate of ‘dementia prevention potential’, 6 articles used LIBRA as a surrogate outcome for their trial or intervention, and 7 articles mentioned that it could help support clinician decisions in practice. Although there is a clear need for tools that can be used for these applications, the amount of evidence supporting the suitability of dementia risk scores for many of these applications is limited. We recommend that researchers transparently report the purposes of these dementia risk scores, which may include causal tasks, and that research is done to evaluate whether it is valid to use these scores in this way.
- 1 January 2026
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 3 (1)
Operationalization of Artificial Intelligence to Assist in Surgical Discharge: A Feasibility Case Study
- 1 January 2026
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 3 (1)
Operationalization of Artificial Intelligence to Assist in Surgical Discharge: A Feasibility Case Study
- Open Access
- 16 July 2025
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 13 (1) , 1-12
Switching from controlled to assisted mechanical ventilation: a multi-center retrospective study (SWITCH)
Background: Switching from controlled to assisted ventilation is crucial in the trajectory of intensive care unit (ICU) stay, but no guidelines exist. We described current practices, analyzed patient characteristics associated with switch success or failure, and explored the feasibility to predict switch failure. Methods: In this retrospective study, we obtained highly granular longitudinal ICU data sets from three medical centers, covering demographics, severity scores, vital signs, ventilation, and laboratory parameters. The primary endpoint was switch success, considering a switch attempt to be successful if a patient did not return to controlled ventilation for the next 72 h while alive, and to be failed otherwise. We compared the characteristics of patients with successful vs. failed first switch attempts at ICU admission, immediately before, and 3 h after the attempt. We trained LASSO logistic regression models to predict switch failure. Results: In 4524/6715 (67%) patients attempting a switch, the first attempt failed. The first switch attempt, regardless of success or failure, was generally made at normalized PaCO2 and pH levels, with PEEP < 10 cmH2O and PaO2/FiO2 indicating mild injury. Despite very similar baseline disease severity, switch failure was associated with significantly worse outcomes, including a 28-day mortality of 27% vs. 16% and median ventilator-free days of 16 vs. 22 (p < 0.001). Failed attempts were initiated significantly earlier than successful ones (median 1.8 vs. 1.3 days, p < 0.001). Before the switch, PaO2/FiO2, if measured at PEEP > 10 cmH2O, and respiratory system compliance was lower in patients with switch failure (median 185 vs. 205 mmHg, p < 0.001; 39 vs. 41 mL/cmH2O, P = 0.001), and post-switch, patients with switch failure experienced greater deterioration in gas exchange and minimal improvement in ventilatory parameters post-switch. Contrary to our hypotheses, patient characteristics for failed vs. successful switches were surprisingly similar, resulting in prediction models with limited discriminative performance. Conclusions: Approximately two-thirds of attempts to switch patients to assisted ventilation fail, which are associated with significantly worse clinical outcomes, despite similar baseline disease severity. Contrary to our hypotheses, patients with successful and failed attempts showed similar characteristics, making switch failure difficult to predict. These findings underscore the importance of preventing switch failures and, given the retrospective nature of this study, highlight the need for prospective studies to better understand the reasons for switch failure and when spontaneous breathing can be safely initiated.
- 16 July 2025
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 13 (1) , 1-12
Open AccessSwitching from controlled to assisted mechanical ventilation: a multi-center retrospective study (SWITCH)
Background: Switching from controlled to assisted ventilation is crucial in the trajectory of intensive care unit (ICU) stay, but no guidelines exist. We described current practices, analyzed patient characteristics associated with switch success or failure, and explored the feasibility to predict switch failure. Methods: In this retrospective study, we obtained highly granular longitudinal ICU data sets from three medical centers, covering demographics, severity scores, vital signs, ventilation, and laboratory parameters. The primary endpoint was switch success, considering a switch attempt to be successful if a patient did not return to controlled ventilation for the next 72 h while alive, and to be failed otherwise. We compared the characteristics of patients with successful vs. failed first switch attempts at ICU admission, immediately before, and 3 h after the attempt. We trained LASSO logistic regression models to predict switch failure. Results: In 4524/6715 (67%) patients attempting a switch, the first attempt failed. The first switch attempt, regardless of success or failure, was generally made at normalized PaCO2 and pH levels, with PEEP < 10 cmH2O and PaO2/FiO2 indicating mild injury. Despite very similar baseline disease severity, switch failure was associated with significantly worse outcomes, including a 28-day mortality of 27% vs. 16% and median ventilator-free days of 16 vs. 22 (p < 0.001). Failed attempts were initiated significantly earlier than successful ones (median 1.8 vs. 1.3 days, p < 0.001). Before the switch, PaO2/FiO2, if measured at PEEP > 10 cmH2O, and respiratory system compliance was lower in patients with switch failure (median 185 vs. 205 mmHg, p < 0.001; 39 vs. 41 mL/cmH2O, P = 0.001), and post-switch, patients with switch failure experienced greater deterioration in gas exchange and minimal improvement in ventilatory parameters post-switch. Contrary to our hypotheses, patient characteristics for failed vs. successful switches were surprisingly similar, resulting in prediction models with limited discriminative performance. Conclusions: Approximately two-thirds of attempts to switch patients to assisted ventilation fail, which are associated with significantly worse clinical outcomes, despite similar baseline disease severity. Contrary to our hypotheses, patients with successful and failed attempts showed similar characteristics, making switch failure difficult to predict. These findings underscore the importance of preventing switch failures and, given the retrospective nature of this study, highlight the need for prospective studies to better understand the reasons for switch failure and when spontaneous breathing can be safely initiated.
- Open Access
- 5 June 2025
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 13 (1) , 1-3
Sub-phenotyping in critical care: a valuable strategy or methodologically fragile path?
- 5 June 2025
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 13 (1) , 1-3
Open AccessSub-phenotyping in critical care: a valuable strategy or methodologically fragile path?
- 29 April 2025
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (5) , e25-e26
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply
- 29 April 2025
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (5) , e25-e26
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply